Brainstorm Cell Therapeutics Inc.
BCLI
$1.20
-$0.02-1.64%
NASDAQ
| 03/31/2025 | 12/31/2024 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -- | -- | |||
| SG&A Expenses | 21.76% | -26.81% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -3.14% | 4.63% | |||
| Operating Income | 3.14% | -4.63% | |||
| Income Before Tax | 3.67% | -9.79% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | 3.67% | -9.79% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 3.67% | -9.79% | |||
| EBIT | 3.14% | -4.63% | |||
| EBITDA | 3.16% | -4.92% | |||
| EPS Basic | 13.29% | -2.12% | |||
| Normalized Basic EPS | 13.30% | -2.10% | |||
| EPS Diluted | 13.29% | -2.12% | |||
| Normalized Diluted EPS | 13.30% | -2.10% | |||
| Average Basic Shares Outstanding | 11.11% | 7.50% | |||
| Average Diluted Shares Outstanding | 11.11% | 7.50% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||